Company: BLTE
Filing Date: 2025-10-22
Form Type: F-3ASR
Source: 0001104659-25-101403
Chunk: 62

Company: BELITE BIO, INC
Filing Date: 2025-10-22
Form: F-3ASR
Chunk 62
---
 managing member of Vestal Point Capital, LLC is Mr. Wilder. As a result, Mr. Wilder may be deemed to have voting and investment power over the securities held by Vestal Point Master Fund and the account separately managed by Vestal Point Capital. Mr. Wilder disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The address of the foregoing entities and Mr. Wilder is c/o Vestal Point Capital, LP, 632 Broadway, Suite 602, New York, NY 10012.

(7)

Consists of (i) 195,312 ADSs/ordinary shares purchased by Mutual Fund Series Trust, on behalf of Eventide Healthcare & Life Sciences Fund (“Eventide Healthcare Fund”) in the 2025 September PIPE and (ii) 195,312 ADSs/ordinary shares issuable upon the exercise of Warrants purchased by Eventide Healthcare Fund in the 2025 September PIPE. Eventide Asset Management, LLC (“Eventide Management”), investment adviser to Eventide Healthcare Fund, holds voting and dispositive power over the shares held by Eventide Healthcare Fund. Robin C. John is the Chief Executive Officer of Eventide Management and Finny Kuruvilla, M.D., Ph.D, is a Co-Chief Investment Officer and Managing Director of Eventide Management. In their corporate capacity for Eventide Management, Mr. John and Dr. Kuruvilla hold voting and/or dispositive power over the shares held by Eventide Healthcare

<div align='center'>42</div>

TABLE OF CONTENTS

Fund. Eventide Management, Mr. John and Dr. Kuruvilla disclaim beneficial ownership of the shares held by Eventide Healthcare Fund, except to the extent of their respective pecuniary interests therein. The address for Eventide Healthcare Fund is Mutual Fund Series Trust, 4221 North 203rd Street, Suite 100, Elkhorn, Nebraska 68022.

(8)

Consists of (a) (i) 156,250 ADSs/ordinary shares purchased by MARSHALL WACE INVESTMENT STRATEGIES — EUREKA FUND (“MW EUREKA FUND”) in the 2025 September PIPE and (ii) 156,250 ADSs/ordinary shares issuable upon the exercise of Warrants purchased by MW EUREKA FUND in the 2025 September PIPE and (b) (i) 31,250 ADSs/ordinary shares purchased by MW XO HEALTH INNO